Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors

NCT02599324 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02599324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02599324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2015
Completion date
August 20, 2021
Enrollment
263 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma, advanced urothelial carcinoma, metastatic colorectal adenocarcinoma, metastatic renal cell carcinoma